Impaired secretion of heart lipoprotein lipase in cyclophosphamide-treated rabbit

Biochim Biophys Acta. 1997 Mar 10;1345(1):77-85. doi: 10.1016/s0005-2760(96)00167-1.

Abstract

Cyclophosphamide administration into fasted rabbits induces a hypertriglyceridaemia and a defect in vascular lipoprotein lipase. Heart LPL activity was more than 50% decreased after antimitotic treatment in fasted animals. The tissue distribution of lipoprotein lipase activity was followed in heart using recycling perfusion. Cyclophosphamide administration resulted in a profound decline in the heparin-releasable lipoprotein lipase activity, concordant with a higher recovery in the residual heart tissue. The effects were more pronounced in fasted than in fed animals. In agreement, the proportion of neosynthesized [35S]methionine-labelled lipoprotein lipase released by heparin was decreased by 50% following antimitotic treatment. The lipolysis of very low density lipoprotein-labelled triacylglycerols was found 2.5-fold reduced in hearts from cyclophosphamide-treated rabbits as compared to controls. These results suggest that a defective secretion of lipoprotein lipase may contribute to the poor expression of lipolytic activity in the vascular bed and to the occurrence of hypertriglyceridaemia during cyclophosphamide treatment.

MeSH terms

  • Animals
  • Coronary Vessels / drug effects
  • Cyclophosphamide / pharmacology*
  • Fasting
  • Heart / drug effects*
  • Heparin / pharmacology
  • Hypertriglyceridemia / chemically induced
  • Hypertriglyceridemia / enzymology
  • Lipolysis
  • Lipoprotein Lipase / analysis*
  • Lipoproteins, VLDL / metabolism
  • Methionine / metabolism
  • Myocardium / enzymology*
  • Perfusion
  • Rabbits
  • Triglycerides / metabolism

Substances

  • Lipoproteins, VLDL
  • Triglycerides
  • very low density lipoprotein triglyceride
  • Cyclophosphamide
  • Heparin
  • Methionine
  • Lipoprotein Lipase